GHRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
GH Research PLC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026
$18.28+0.13 (+0.72%)
Close on Oct 19, 2026
- Market cap
- $1.22B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns GH Research's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Weston Nichols | 9,456,622 | 15.20% | 13G (passive) amendment | Mar 31, 2026 |
| Bvf Inc/Il | 8,827,712 | 14.20% | 13G (passive) amendment | Mar 31, 2025 |
| Rajeev Shah | 6,944,648 | 11.20% | 13G (passive) amendment | Mar 31, 2025 |
| Roderick Wong, M.D. | 5,499,769 | 8.90% | 13G (passive) amendment | Mar 31, 2025 |
| FMR LLC | 5,092,145 | 8.20% | 13G (passive) amendment | Jun 30, 2025 |
| RA Capital Management, L.P. | 4,897,182 | 7.10% | 13G (passive) amendment | Aug 12, 2026 |
| Abigail P. Johnson | 4,249,580 | 6.90% | 13G (passive) | Mar 31, 2025 |
| Lynx1 Capital Management LP | 13,263,288 | 19.30% | 13G (passive) amendment | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Aaron Luke Cameron | Chief Operating Officer | – | – | Apr 2, 2026 |
| Julie Ryan | VP, Finance | – | – | Apr 2, 2026 |
| Velichka Valcheva | Chief Executive Officer | – | – | Apr 2, 2026 |
| Magnus Clemensen Halle | Managing Director, Ireland | 118,354 | 0.19% | Apr 2, 2026 |
| Florian Schonharting | Director | 14,824,419 | 23.90% | Sep 9, 2026 |
| Dermot John Hanley | Director | 2,432 | 0.00% | Aug 13, 2026 |
| Michael Forer | Director | 45,509 | 0.07% | Aug 13, 2026 |
| Duncan Moore | Director | 14,600 | 0.02% | Aug 13, 2026 |